Search

Your search keyword '"Clarke, C.S."' showing total 20 results
Start Over Author "Clarke, C.S."
20 results on '"Clarke, C.S."'

1. Patient deprivation and perceived scan burden negatively impact the quality of whole-body MRI

Author

Aboagye, A., Agoramoorthy, L., Ahmed, S., Amadi, A., Anand, G., Atkin, G., Austria, A., Ball, S., Bazari, F., Beable, R., Beare, S., Beedham, H., Beeston, T., Bharwani, N., Bhatnagar, G., Bhowmik, A., Blakeway, L., Blunt, D., Boavida, P., Boisfer, D., Breen, D., Bridgewater, J., Burke, S., Butawan, R., Campbell, Y., Chang, E., Chao, D., Chukundah, S., Clarke, C.S., Collins, B., Collins, C., Conteh, V., Couture, J., Crosbie, J., Curtis, H., Daniel, A., Davis, L., Desai, K., Duggan, M., Ellis, S., Elton, C., Engledow, A., Everitt, C., Ferdous, S., Frow, A., Furneaux, M., Gibbons, N., Glynne-Jones, R., Gogbashian, A., Goh, V., Gourtsoyianni, S., Green, A., Green, Laura, Green, Liz, Groves, A., Guthrie, A., Hadley, E., Halligan, S., Hameeduddin, A., Hanid, G., Hans, S., Hans, B., Higginson, A., Honeyfield, L., Hughes, H., Hughes, J., Hurl, L., Isaac, E., Jackson, M., Jalloh, A., Janes, S., Jannapureddy, R., Jayme, A., Johnson, A., Johnson, E., Julka, P., Kalasthry, J., Karapanagiotou, E., Karp, S., Kay, C., Kellaway, J., Khan, S., Koh, D., Light, T., Limbu, P., Lock, S., Locke, I., Loke, T., Lowe, A., Lucas, N., Maheswaran, S., Mallett, S., Marwood, E., McGowan, J., Mckirdy, F., Mills-Baldock, T., Moon, T., Morgan, V., Morris, S., Morton, A., Nasseri, S., Navani, N., Nichols, P., Norman, C., Ntala, E., Nunes, A., Obichere, A., O'Donohue, J., Olaleye, I., Oliver, A., Onajobi, A., O'Shaughnessy, T., Padhani, A., Pardoe, H., Partridge, W., Patel, U., Perry, K., Piga, W., Prezzi, D., Prior, K., Punwani, S., Pyers, J., Rafiee, H., Rahman, F., Rajanpandian, I., Ramesh, S., Raouf, S., Reczko, K., Reinhardt, A., Robinson, D., Rockall, A., Russell, P., Sargus, K., Scurr, E., Shahabuddin, K., Sharp, A., Shepherd, B., Shiu, K., Sidhu, H., Simcock, I., Simeon, C., Smith, A., Smith, D., Snell, D., Spence, J., Srirajaskanthan, R., Stachini, V., Stegner, S., Stirling, J., Strickland, N., Tarver, K., Teague, J., Thaha, M., Train, M., Tulmuntaha, S., Tunariu, N., van Ree, K., Verjee, A., Wanstall, C., Weir, S., Wijeyekoon, S., Wilson, J., Wilson, S., Win, T., Woodrow, L., Yu, D., Evans, R.E.C., Taylor, S.A., Sakai, N.S., and Miles, A.

Published
2020
Full Text
View/download PDF

2. Proton versus photon therapy for esophageal cancer – A trimodality strategy (PROTECT) NCT050555648

Author

Mortensen, H.R., primary, Populaire, P., additional, Hoffmann, L., additional, Moeller, D.S., additional, Appelt, A., additional, Nafteux, P., additional, Muijs, C.T., additional, Grau, C., additional, Hawkins, M.A., additional, Troost, E.G.C., additional, Defraene, G., additional, Canters, R., additional, Clarke, C.S., additional, Weber, D.C., additional, Korevaar, E.W., additional, Haustermans, K., additional, Nordsmark, M., additional, Gebski, Val, additional, Achiam, M.P., additional, Markar, Sheraz R., additional, Radhakrishna, Ganesh, additional, Berbee, Maaike, additional, Scartoni, Daniele, additional, Orlandi, Ester, additional, Doyen, Jerome, additional, Gregoire, Vincent, additional, Crehange, Gilles, additional, Langendijk, Johannes, additional, Lorgelly, Paula, additional, Blommenstein, Hedwig M., additional, Byskov, Camilla S., additional, Ehmsen, Mai L., additional, Jensen, Maria Fuglsang, additional, Freixas, Gloria Vilches, additional, and Bütoft, Rebecca, additional

Published
2024
Full Text
View/download PDF

3. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

Author

Gillessen, S. Bossi, A. Davis, I.D. de Bono, J. Fizazi, K. James, N.D. Mottet, N. Shore, N. Small, E. Smith, M. Sweeney, C.J. Tombal, B. Antonarakis, E.S. Aparicio, A.M. Armstrong, A.J. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Blanchard, P. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Castellano, D. Castro, E. Cheng, H.H. Chi, K.N. Chowdhury, S. Clarke, C.S. Clarke, N. Daugaard, G. De Santis, M. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Ekeke, O.N. Evans, C.P. Fanti, S. Feng, F.Y. Fonteyne, V. Fossati, N. Frydenberg, M. George, D. Gleave, M. Gravis, G. Halabi, S. Heinrich, D. Herrmann, K. Higano, C. Hofman, M.S. Horvath, L.G. Hussain, M. Jereczek-Fossa, B.A. Jones, R. Kanesvaran, R. Kellokumpu-Lehtinen, P.-L. Khauli, R.B. Klotz, L. Kramer, G. Leibowitz, R. Logothetis, C. Mahal, B. Maluf, F. Mateo, J. Matheson, D. Mehra, N. Merseburger, A. Morgans, A.K. Morris, M.J. Mrabti, H. Mukherji, D. Murphy, D.G. Murthy, V. Nguyen, P.L. Oh, W.K. Ost, P. O'Sullivan, J.M. Padhani, A.R. Pezaro, C.J. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M.A. Ryan, C.J. Saad, F. Sade, J.P. Sartor, O. Scher, H.I. Sharifi, N. Skoneczna, I. Soule, H. Spratt, D.E. Srinivas, S. Sternberg, C.N. Steuber, T. Suzuki, H. Sydes, M.R. Taplin, M.-E. Tilki, D. Türkeri, L. Turco, F. Uemura, H. Uemura, H. Ürün, Y. Vale, C.L. van Oort, I. Vapiwala, N. Walz, J. Yamoah, K. Ye, D. Yu, E.Y. Zapatero, A. Zilli, T. Omlin, A. and Gillessen, S. Bossi, A. Davis, I.D. de Bono, J. Fizazi, K. James, N.D. Mottet, N. Shore, N. Small, E. Smith, M. Sweeney, C.J. Tombal, B. Antonarakis, E.S. Aparicio, A.M. Armstrong, A.J. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Blanchard, P. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Castellano, D. Castro, E. Cheng, H.H. Chi, K.N. Chowdhury, S. Clarke, C.S. Clarke, N. Daugaard, G. De Santis, M. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Ekeke, O.N. Evans, C.P. Fanti, S. Feng, F.Y. Fonteyne, V. Fossati, N. Frydenberg, M. George, D. Gleave, M. Gravis, G. Halabi, S. Heinrich, D. Herrmann, K. Higano, C. Hofman, M.S. Horvath, L.G. Hussain, M. Jereczek-Fossa, B.A. Jones, R. Kanesvaran, R. Kellokumpu-Lehtinen, P.-L. Khauli, R.B. Klotz, L. Kramer, G. Leibowitz, R. Logothetis, C. Mahal, B. Maluf, F. Mateo, J. Matheson, D. Mehra, N. Merseburger, A. Morgans, A.K. Morris, M.J. Mrabti, H. Mukherji, D. Murphy, D.G. Murthy, V. Nguyen, P.L. Oh, W.K. Ost, P. O'Sullivan, J.M. Padhani, A.R. Pezaro, C.J. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M.A. Ryan, C.J. Saad, F. Sade, J.P. Sartor, O. Scher, H.I. Sharifi, N. Skoneczna, I. Soule, H. Spratt, D.E. Srinivas, S. Sternberg, C.N. Steuber, T. Suzuki, H. Sydes, M.R. Taplin, M.-E. Tilki, D. Türkeri, L. Turco, F. Uemura, H. Uemura, H. Ürün, Y. Vale, C.L. van Oort, I. Vapiwala, N. Walz, J. Yamoah, K. Ye, D. Yu, E.Y. Zapatero, A. Zilli, T. Omlin, A.

Abstract

Background: Innovations in imaging and molecular characterisation together with novel treatment options have improved outcomes in advanced prostate cancer. However, we still lack high-level evidence in many areas relevant to making management decisions in daily clinical practise. The 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) addressed some questions in these areas to supplement guidelines that mostly are based on level 1 evidence. Objective: To present the voting results of the APCCC 2022. Design, setting, and participants: The experts voted on controversial questions where high-level evidence is mostly lacking: locally advanced prostate cancer; biochemical recurrence after local treatment; metastatic hormone-sensitive, non-metastatic, and metastatic castration-resistant prostate cancer; oligometastatic prostate cancer; and managing side effects of hormonal therapy. A panel of 105 international prostate cancer experts voted on the consensus questions. Outcome measurements and statistical analysis: The panel voted on 198 pre-defined questions, which were developed by 117 voting and non-voting panel members prior to the conference following a modified Delphi process. A total of 116 questions on metastatic and/or castration-resistant prostate cancer are discussed in this manuscript. In 2022, the voting was done by a web-based survey because of COVID-19 restrictions. Results and limitations: The voting reflects the expert opinion of these panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results are reported in the supplementary material. We report here on topics in metastatic, hormone-sensitive prostate cancer (mHSPC), non-metastatic, castration-resistant prostate cancer (nmCRPC), metastatic castration-resistant prostate cancer (mCRPC), and oligometastatic an

Published
2023

4. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Author

Gillessen, S. Bossi, A. Davis, I.D. de Bono, J. Fizazi, K. James, N.D. Mottet, N. Shore, N. Small, E. Smith, M. Sweeney, C. Tombal, B. Antonarakis, E.S. Aparicio, A.M. Armstrong, A.J. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Blanchard, P. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Castellano, D. Castro, E. Cheng, H.H. Chi, K.N. Chowdhury, S. Clarke, C.S. Clarke, N. Daugaard, G. De Santis, M. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Ngozi Ekeke, O. Evans, C.P. Fanti, S. Feng, F.Y. Fonteyne, V. Fossati, N. Frydenberg, M. George, D. Gleave, M. Gravis, G. Halabi, S. Heinrich, D. Herrmann, K. Higano, C. Hofman, M.S. Horvath, L.G. Hussain, M. Jereczek-Fossa, B.A. Jones, R. Kanesvaran, R. Kellokumpu-Lehtinen, P.-L. Khauli, R.B. Klotz, L. Kramer, G. Leibowitz, R. Logothetis, C.J. Mahal, B.A. Maluf, F. Mateo, J. Matheson, D. Mehra, N. Merseburger, A. Morgans, A.K. Morris, M.J. Mrabti, H. Mukherji, D. Murphy, D.G. Murthy, V. Nguyen, P.L. Oh, W.K. Ost, P. O'Sullivan, J.M. Padhani, A.R. Pezaro, C. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M.A. Ryan, C.J. Saad, F. Pablo Sade, J. Sartor, O.A. Scher, H.I. Sharifi, N. Skoneczna, I. Soule, H. Spratt, D.E. Srinivas, S. Sternberg, C.N. Steuber, T. Suzuki, H. Sydes, M.R. Taplin, M.-E. Tilki, D. Türkeri, L. Turco, F. Uemura, H. Uemura, H. Ürün, Y. Vale, C.L. van Oort, I. Vapiwala, N. Walz, J. Yamoah, K. Ye, D. Yu, E.Y. Zapatero, A. Zilli, T. Omlin, A. and Gillessen, S. Bossi, A. Davis, I.D. de Bono, J. Fizazi, K. James, N.D. Mottet, N. Shore, N. Small, E. Smith, M. Sweeney, C. Tombal, B. Antonarakis, E.S. Aparicio, A.M. Armstrong, A.J. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Blanchard, P. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Castellano, D. Castro, E. Cheng, H.H. Chi, K.N. Chowdhury, S. Clarke, C.S. Clarke, N. Daugaard, G. De Santis, M. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Ngozi Ekeke, O. Evans, C.P. Fanti, S. Feng, F.Y. Fonteyne, V. Fossati, N. Frydenberg, M. George, D. Gleave, M. Gravis, G. Halabi, S. Heinrich, D. Herrmann, K. Higano, C. Hofman, M.S. Horvath, L.G. Hussain, M. Jereczek-Fossa, B.A. Jones, R. Kanesvaran, R. Kellokumpu-Lehtinen, P.-L. Khauli, R.B. Klotz, L. Kramer, G. Leibowitz, R. Logothetis, C.J. Mahal, B.A. Maluf, F. Mateo, J. Matheson, D. Mehra, N. Merseburger, A. Morgans, A.K. Morris, M.J. Mrabti, H. Mukherji, D. Murphy, D.G. Murthy, V. Nguyen, P.L. Oh, W.K. Ost, P. O'Sullivan, J.M. Padhani, A.R. Pezaro, C. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M.A. Ryan, C.J. Saad, F. Pablo Sade, J. Sartor, O.A. Scher, H.I. Sharifi, N. Skoneczna, I. Soule, H. Spratt, D.E. Srinivas, S. Sternberg, C.N. Steuber, T. Suzuki, H. Sydes, M.R. Taplin, M.-E. Tilki, D. Türkeri, L. Turco, F. Uemura, H. Uemura, H. Ürün, Y. Vale, C.L. van Oort, I. Vapiwala, N. Walz, J. Yamoah, K. Ye, D. Yu, E.Y. Zapatero, A. Zilli, T. Omlin, A.

Abstract

Background: Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management. Objective: To present consensus voting results for select questions from APCCC 2022. Design, setting, and participants: Before the conference, a panel of 117 international prostate cancer experts used a modified Delphi process to develop 198 multiple-choice consensus questions on (1) intermediate- and high-risk and locally advanced prostate cancer, (2) biochemical recurrence after local treatment, (3) side effects from hormonal therapies, (4) metastatic hormone-sensitive prostate cancer, (5) nonmetastatic castration-resistant prostate cancer, (6) metastatic castration-resistant prostate cancer, and (7) oligometastatic and oligoprogressive prostate cancer. Before the conference, these questions were administered via a web-based survey to the 105 physician panel members (“panellists”) who directly engage in prostate cancer treatment decision-making. Herein, we present results for the 82 questions on topics 1–3. Outcome measurements and statistical analysis: Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. Results and limitations: The voting results reveal varying degrees of consensus, as is discussed in this article and shown in the detailed results in the Supplementary material. The findings reflect the opinions of an international panel of experts and did not incorporate a formal literature review and meta-analysis. Conclusions: These voting results by a panel of international experts in advanced prostate cancer can help physicians and patients navigate controversial areas of clinical manage

Published
2023

5. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Author

Gillessen, S., Bossi, A., Davis, I.D., Bono, J. de, Fizazi, K., James, N.D., Mottet, N., Shore, N., Small, E., Smith, M., Sweeney, C., Tombal, B., Antonarakis, E.S., Aparicio, A.M., Armstrong, A.J., Attard, G., Beer, T.M., Beltran, H., Bjartell, A., Blanchard, P., Briganti, A., Bristow, R.G., Bulbul, M., Caffo, O., Castellano, D., Castro, E., Cheng, H.H., Chi, K.N., Chowdhury, S., Clarke, C.S., Clarke, N., Daugaard, G., Santis, M. de, Duran, I., Eeles, R., Efstathiou, E., Efstathiou, J., Ekeke, O. Ngozi, Evans, C.P., Fanti, S., Feng, F.Y., Fonteyne, V., Fossati, N., Frydenberg, M., George, D., Gleave, M., Gravis, G., Halabi, S., Heinrich, D., Herrmann, K., Higano, C., Hofman, M.S., Horvath, L.G., Hussain, M., Jereczek-Fossa, Barbara A., Jones, R., Kanesvaran, R., Kellokumpu-Lehtinen, P.L., Khauli, R.B., Klotz, L., Kramer, G., Leibowitz, R., Logothetis, C.J., Mahal, B.A., Maluf, F. Cotait, Mateo, J., Matheson, D., Mehra, N., Merseburger, A., Morgans, A.K., Morris, M.J., Mrabti, H., Mukherji, D., Murphy, D.G.M., Murthy, V., Nguyen, P.L., Oh, W.K., Ost, P., O'Sullivan, J.M., Padhani, A.R., Pezaro, C., Poon, D.M.C., Pritchard, C.C., Rabah, D.M., Rathkopf, D., Reiter, R.E., Rubin, M.A., Ryan, C.J., Saad, F., Sade, J. Pablo, Sartor, O.A., Scher, H.I., Sharifi, N., Skoneczna, I., Soule, H., Spratt, D.E., Srinivas, S., Sternberg, C.N., Steuber, T., Oort, I.M. van, Zilli, T., Omlin, A., Gillessen, S., Bossi, A., Davis, I.D., Bono, J. de, Fizazi, K., James, N.D., Mottet, N., Shore, N., Small, E., Smith, M., Sweeney, C., Tombal, B., Antonarakis, E.S., Aparicio, A.M., Armstrong, A.J., Attard, G., Beer, T.M., Beltran, H., Bjartell, A., Blanchard, P., Briganti, A., Bristow, R.G., Bulbul, M., Caffo, O., Castellano, D., Castro, E., Cheng, H.H., Chi, K.N., Chowdhury, S., Clarke, C.S., Clarke, N., Daugaard, G., Santis, M. de, Duran, I., Eeles, R., Efstathiou, E., Efstathiou, J., Ekeke, O. Ngozi, Evans, C.P., Fanti, S., Feng, F.Y., Fonteyne, V., Fossati, N., Frydenberg, M., George, D., Gleave, M., Gravis, G., Halabi, S., Heinrich, D., Herrmann, K., Higano, C., Hofman, M.S., Horvath, L.G., Hussain, M., Jereczek-Fossa, Barbara A., Jones, R., Kanesvaran, R., Kellokumpu-Lehtinen, P.L., Khauli, R.B., Klotz, L., Kramer, G., Leibowitz, R., Logothetis, C.J., Mahal, B.A., Maluf, F. Cotait, Mateo, J., Matheson, D., Mehra, N., Merseburger, A., Morgans, A.K., Morris, M.J., Mrabti, H., Mukherji, D., Murphy, D.G.M., Murthy, V., Nguyen, P.L., Oh, W.K., Ost, P., O'Sullivan, J.M., Padhani, A.R., Pezaro, C., Poon, D.M.C., Pritchard, C.C., Rabah, D.M., Rathkopf, D., Reiter, R.E., Rubin, M.A., Ryan, C.J., Saad, F., Sade, J. Pablo, Sartor, O.A., Scher, H.I., Sharifi, N., Skoneczna, I., Soule, H., Spratt, D.E., Srinivas, S., Sternberg, C.N., Steuber, T., Oort, I.M. van, Zilli, T., and Omlin, A.

Abstract

Item does not contain fulltext, BACKGROUND: Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management. OBJECTIVE: To present consensus voting results for select questions from APCCC 2022. DESIGN, SETTING, AND PARTICIPANTS: Before the conference, a panel of 117 international prostate cancer experts used a modified Delphi process to develop 198 multiple-choice consensus questions on (1) intermediate- and high-risk and locally advanced prostate cancer, (2) biochemical recurrence after local treatment, (3) side effects from hormonal therapies, (4) metastatic hormone-sensitive prostate cancer, (5) nonmetastatic castration-resistant prostate cancer, (6) metastatic castration-resistant prostate cancer, and (7) oligometastatic and oligoprogressive prostate cancer. Before the conference, these questions were administered via a web-based survey to the 105 physician panel members ("panellists") who directly engage in prostate cancer treatment decision-making. Herein, we present results for the 82 questions on topics 1-3. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. RESULTS AND LIMITATIONS: The voting results reveal varying degrees of consensus, as is discussed in this article and shown in the detailed results in the Supplementary material. The findings reflect the opinions of an international panel of experts and did not incorporate a formal literature review and meta-analysis. CONCLUSIONS: These voting results by a panel of international experts in advanced prostate cancer can help physicians and patients navigate controversial areas of clinical manage

Published
2023

6. 782TiP Reduced frequency immune checkpoint inhibition in cancers (REFINE): A multi-arm phase II trial testing reduced intensity immunotherapy in different cancers

Author

Merrick, S., primary, Nankivell, M., additional, Griffiths, T., additional, Hudson, W., additional, Clarke, C.S., additional, Bray, G., additional, Forcat, S., additional, Campos, M., additional, Bryant, H., additional, Quartagno, M., additional, Langley, R., additional, Pickering, L.M., additional, Vasudev, N.S., additional, and Gilbert, D., additional

Published
2022
Full Text
View/download PDF

7. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021

Author

Gillessen, S. Armstrong, A. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Bossi, A. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Chi, K.N. Clarke, C.S. Clarke, N. Davis, I.D. de Bono, J.S. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Ekeke, O.N. Evans, C.P. Fanti, S. Feng, F.Y. Fizazi, K. Frydenberg, M. George, D. Gleave, M. Halabi, S. Heinrich, D. Higano, C. Hofman, M.S. Hussain, M. James, N. Jones, R. Kanesvaran, R. Khauli, R.B. Klotz, L. Leibowitz, R. Logothetis, C. Maluf, F. Millman, R. Morgans, A.K. Morris, M.J. Mottet, N. Mrabti, H. Murphy, D.G. Murthy, V. Oh, W.K. Ost, P. O'Sullivan, J.M. Padhani, A.R. Parker, C. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M. Ryan, C.J. Saad, F. Sade, J.P. Sartor, O. Scher, H.I. Shore, N. Skoneczna, I. Small, E. Smith, M. Soule, H. Spratt, D.E. Sternberg, C.N. Suzuki, H. Sweeney, C. Sydes, M.R. Taplin, M.-E. Tilki, D. Tombal, B. Türkeri, L. Uemura, H. Uemura, H. van Oort, I. Yamoah, K. Ye, D. Zapatero, A. Omlin, A. and Gillessen, S. Armstrong, A. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Bossi, A. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Chi, K.N. Clarke, C.S. Clarke, N. Davis, I.D. de Bono, J.S. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Ekeke, O.N. Evans, C.P. Fanti, S. Feng, F.Y. Fizazi, K. Frydenberg, M. George, D. Gleave, M. Halabi, S. Heinrich, D. Higano, C. Hofman, M.S. Hussain, M. James, N. Jones, R. Kanesvaran, R. Khauli, R.B. Klotz, L. Leibowitz, R. Logothetis, C. Maluf, F. Millman, R. Morgans, A.K. Morris, M.J. Mottet, N. Mrabti, H. Murphy, D.G. Murthy, V. Oh, W.K. Ost, P. O'Sullivan, J.M. Padhani, A.R. Parker, C. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M. Ryan, C.J. Saad, F. Sade, J.P. Sartor, O. Scher, H.I. Shore, N. Skoneczna, I. Small, E. Smith, M. Soule, H. Spratt, D.E. Sternberg, C.N. Suzuki, H. Sweeney, C. Sydes, M.R. Taplin, M.-E. Tilki, D. Tombal, B. Türkeri, L. Uemura, H. Uemura, H. van Oort, I. Yamoah, K. Ye, D. Zapatero, A. Omlin, A.

Abstract

Background: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. The 2021 Advanced Prostate Cancer Consensus Conference (APCCC) addressed some of these questions to supplement guidelines that are based on level 1 evidence. Objective: To present the voting results from APCCC 2021. Design, setting, and participants: The experts identified three major areas of controversy related to management of advanced prostate cancer: newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), the use of prostate-specific membrane antigen ligands in diagnostics and therapy, and molecular characterisation of tissue and blood. A panel of 86 international prostate cancer experts developed the programme and the consensus questions. Outcome measurements and statistical analysis: The panel voted publicly but anonymously on 107 pre-defined questions, which were developed by both voting and non-voting panel members prior to the conference following a modified Delphi process. Results and limitations: The voting reflected the opinions of panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results reported in the Supplementary material. Conclusions: These voting results from a panel of experts in advanced prostate cancer can help clinicians and patients to navigate controversial areas of management for which high-level evidence is scant. However, diagnostic and treatment decisions should always be individualised according to patient characteristics, such as the extent and location of disease, prior treatment(s), comorbidities, patient preferences, and treatment recommendations, and should also incorporate current and emerging clinical eviden

Published
2022

8. Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021

Author

Tilki, Derya, Gillessen, S.; Armstron, A.; Attard, G.; Beer, T.M.; Beltran, H.; Bjartell, A.; Bossi, A.; Briganti, A.; Bristow, R.G.; Bulbul, M.; Caffo, O.; Chi, K.N.; Clarke, C.S.; Clarke, N.; Davis, I.D.; de Bono, J.S.; Duran, I.; Eeles, R.; Efstathiou, E.; Efstathiou, J.; Ekeke, O.N.; Evans, C.P.; Fanti, S.; Feng, F.Y.; Fizazi, K.; Frydenberg, M.; George, D.; Gleave, M.; Halabi, S.; Heinrich, D.; Higano, C.; Hofman, M.S.; Hussain, M.; James, N.; Jones, R.; Kanesvaran, R.; Khauli, R.B.; Klotz, L.; Leibowitz, R.; Logothetis, C.; Maluf, F.; Millman, R.; Morgans, A.K.; Morris, M.J.; Mottet, N.; Mrabti, H.; Murphy, D.G.; Murthy, V.; Oh, W.K.; Ost, P.; O'Sullivan, J.M.; Padhani, A.R.; Parker, C.; Poon, D.M.C.; Pritchard, C.C.; Rabah, D.M.; Rathkopf, D.; Reiter, R.E.; Rubin, M.; Ryan, C.J.; Saad, F.; Sade, J.P.; Sartor, O.; Scher, H.I.; Shore, N.; Skoneczna, I.; Small, E.; Smith, M.; Soule, H.; Spratt, D.E.; Sternberg, C.N.; Suzuki, H.; Sweeney, C.; Sydes, M.R.; Taplin, M.E.; Tombal, B.; Türkeri, L.; Uemura, H.; Uemura, H.; van Oort, I., Yamoah, K.; Ye, D.; Zapatero, A.; Omlin, A., Koç University Hospital, School of Medicine, Tilki, Derya, Gillessen, S.; Armstron, A.; Attard, G.; Beer, T.M.; Beltran, H.; Bjartell, A.; Bossi, A.; Briganti, A.; Bristow, R.G.; Bulbul, M.; Caffo, O.; Chi, K.N.; Clarke, C.S.; Clarke, N.; Davis, I.D.; de Bono, J.S.; Duran, I.; Eeles, R.; Efstathiou, E.; Efstathiou, J.; Ekeke, O.N.; Evans, C.P.; Fanti, S.; Feng, F.Y.; Fizazi, K.; Frydenberg, M.; George, D.; Gleave, M.; Halabi, S.; Heinrich, D.; Higano, C.; Hofman, M.S.; Hussain, M.; James, N.; Jones, R.; Kanesvaran, R.; Khauli, R.B.; Klotz, L.; Leibowitz, R.; Logothetis, C.; Maluf, F.; Millman, R.; Morgans, A.K.; Morris, M.J.; Mottet, N.; Mrabti, H.; Murphy, D.G.; Murthy, V.; Oh, W.K.; Ost, P.; O'Sullivan, J.M.; Padhani, A.R.; Parker, C.; Poon, D.M.C.; Pritchard, C.C.; Rabah, D.M.; Rathkopf, D.; Reiter, R.E.; Rubin, M.; Ryan, C.J.; Saad, F.; Sade, J.P.; Sartor, O.; Scher, H.I.; Shore, N.; Skoneczna, I.; Small, E.; Smith, M.; Soule, H.; Spratt, D.E.; Sternberg, C.N.; Suzuki, H.; Sweeney, C.; Sydes, M.R.; Taplin, M.E.; Tombal, B.; Türkeri, L.; Uemura, H.; Uemura, H.; van Oort, I., Yamoah, K.; Ye, D.; Zapatero, A.; Omlin, A., Koç University Hospital, and School of Medicine

Abstract

Background: innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. The 2021 Advanced Prostate Cancer Consensus Conference (APCCC) addressed some of these questions to supplement guidelines that are based on level 1 evidence. Objective: to present the voting results from APCCC 2021. Design, setting, and participants: the experts identified three major areas of controversy related to management of advanced prostate cancer: newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), the use of prostate-specific membrane antigen ligands in diagnostics and therapy, and molecular characterisation of tissue and blood. A panel of 86 international prostate cancer experts developed the programme and the consensus questions. Outcome measurements and statistical analysis: The panel voted publicly but anonymously on 107 pre-defined questions, which were developed by both voting and non-voting panel members prior to the conference following a modified Delphi process. Results and limitations: the voting reflected the opinions of panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results reported in the Supplementary material. Conclusions: these voting results from a panel of experts in advanced prostate cancer can help clinicians and patients to navigate controversial areas of management for which high-level evidence is scant. However, diagnostic and treatment decisions should always be individualised according to patient characteristics, such as the extent and location of disease, prior treatment(s), comorbidities, patient preferences, and treatment recommendations, and should also incorporate current and emerging clinical eviden, National Health and Medical Research Council (NHMRC) Practitioner Fellowship; Prostate Cancer Foundation; Peter MacCallum Foundation; NHMRC Investigator Grant

Published
2022

9. What experts think about prostate cancer management during the COVID-19 pandemic: report from The Advanced Prostate Cancer Consensus Conference 2021

Author

Tilki, Derya, Turco, F.; Armstrong, A.; Attard, G.; Beer, T.M.; Beltran, H.; Bjartell, A.; Bossi, A.; Briganti, A.; Bristow, R.G.; Bulbul, M.; Caffo, O.; Chi, K.N.; Clarke, C.S.; Clarke, N.; Davis, I.D.; de Bono, J.; Duran, I.; Eeles, R.; Efstathiou, E.; Efstathiou, J.; Evans, C.P.; Fanti, S.; Feng, F.Y.; Fizazi, K.; Frydenberg, M.; George, D.; Gleave, M.; Halabi, S.; Heinrich, D.; Higano, C.; Hofman, M.S.; Hussain, M.; James, N.; Jones, R.; Kanesvaran, R.; Khauli, R.B.; Klotz, L.; Leibowitz, R.; Logothetis, C.; Maluf, F.; Millman, R.; Morgans, A.K.; Morris, M.J.; Mottet, N.; Mrabti, H.; Murphy, D.G.; Murthy, V.; Oh, W.K.; Ekeke, O.N.; Ost, P.; O'Sullivan, J.M.; Padhani, A.R.; Parker, C.; Poon, D.M.C.; Pritchard, C.C.; Rabah, D.M.; Rathkopf, D.; Reiter, R.E.; Rubin, M.; Ryan, C.J.; Saad, F.; Sade, J.P.; Sartor, O.; Scher, H.I.; Shore, N.; Skoneczna, I.; Small, E.; Smith, M.; Soule, H.; Spratt, D.E.; Sternberg, C.N.; Suzuki, H.; Sweeney, C.; Sydes, M.R.; Taplin, M.-E.; Tombal, B.; Türkeri, L.; Uemura, H.; Uemura, H.; van Oort, I.; Yamoah, K.; Ye, D.; Zapatero, A.; Gillessen, S.; Omlin, A., Koç University Hospital, School of Medicine, Tilki, Derya, Turco, F.; Armstrong, A.; Attard, G.; Beer, T.M.; Beltran, H.; Bjartell, A.; Bossi, A.; Briganti, A.; Bristow, R.G.; Bulbul, M.; Caffo, O.; Chi, K.N.; Clarke, C.S.; Clarke, N.; Davis, I.D.; de Bono, J.; Duran, I.; Eeles, R.; Efstathiou, E.; Efstathiou, J.; Evans, C.P.; Fanti, S.; Feng, F.Y.; Fizazi, K.; Frydenberg, M.; George, D.; Gleave, M.; Halabi, S.; Heinrich, D.; Higano, C.; Hofman, M.S.; Hussain, M.; James, N.; Jones, R.; Kanesvaran, R.; Khauli, R.B.; Klotz, L.; Leibowitz, R.; Logothetis, C.; Maluf, F.; Millman, R.; Morgans, A.K.; Morris, M.J.; Mottet, N.; Mrabti, H.; Murphy, D.G.; Murthy, V.; Oh, W.K.; Ekeke, O.N.; Ost, P.; O'Sullivan, J.M.; Padhani, A.R.; Parker, C.; Poon, D.M.C.; Pritchard, C.C.; Rabah, D.M.; Rathkopf, D.; Reiter, R.E.; Rubin, M.; Ryan, C.J.; Saad, F.; Sade, J.P.; Sartor, O.; Scher, H.I.; Shore, N.; Skoneczna, I.; Small, E.; Smith, M.; Soule, H.; Spratt, D.E.; Sternberg, C.N.; Suzuki, H.; Sweeney, C.; Sydes, M.R.; Taplin, M.-E.; Tombal, B.; Türkeri, L.; Uemura, H.; Uemura, H.; van Oort, I.; Yamoah, K.; Ye, D.; Zapatero, A.; Gillessen, S.; Omlin, A., Koç University Hospital, and School of Medicine

Abstract

Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert's treatment recommendations are influenced by the vaccination status: the COVID-19 pandemic altered management of APC patients for 70% of the panellists before the vaccination was available but only for 25% of panellists for fully vaccinated patients. Most experts (71%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients. Patient summary: In the Advanced Prostate Cancer Consensus Conference 2021, the panellists reached a consensus regarding the recommendation of the COVID-19 vaccine in prostate cancer patients and use of telemedicine for monitoring these patients., NA

Published
2022

11. Patient deprivation and perceived scan burden negatively impact the quality of whole-body MRI

Author

Evans, R.E.C., primary, Taylor, S.A., additional, Kalasthry, J., additional, Sakai, N.S., additional, Miles, A., additional, Aboagye, A., additional, Agoramoorthy, L., additional, Ahmed, S., additional, Amadi, A., additional, Anand, G., additional, Atkin, G., additional, Austria, A., additional, Ball, S., additional, Bazari, F., additional, Beable, R., additional, Beare, S., additional, Beedham, H., additional, Beeston, T., additional, Bharwani, N., additional, Bhatnagar, G., additional, Bhowmik, A., additional, Blakeway, L., additional, Blunt, D., additional, Boavida, P., additional, Boisfer, D., additional, Breen, D., additional, Bridgewater, J., additional, Burke, S., additional, Butawan, R., additional, Campbell, Y., additional, Chang, E., additional, Chao, D., additional, Chukundah, S., additional, Clarke, C.S., additional, Collins, B., additional, Collins, C., additional, Conteh, V., additional, Couture, J., additional, Crosbie, J., additional, Curtis, H., additional, Daniel, A., additional, Davis, L., additional, Desai, K., additional, Duggan, M., additional, Ellis, S., additional, Elton, C., additional, Engledow, A., additional, Everitt, C., additional, Ferdous, S., additional, Frow, A., additional, Furneaux, M., additional, Gibbons, N., additional, Glynne-Jones, R., additional, Gogbashian, A., additional, Goh, V., additional, Gourtsoyianni, S., additional, Green, A., additional, Green, Laura, additional, Green, Liz, additional, Groves, A., additional, Guthrie, A., additional, Hadley, E., additional, Halligan, S., additional, Hameeduddin, A., additional, Hanid, G., additional, Hans, S., additional, Hans, B., additional, Higginson, A., additional, Honeyfield, L., additional, Hughes, H., additional, Hughes, J., additional, Hurl, L., additional, Isaac, E., additional, Jackson, M., additional, Jalloh, A., additional, Janes, S., additional, Jannapureddy, R., additional, Jayme, A., additional, Johnson, A., additional, Johnson, E., additional, Julka, P., additional, Karapanagiotou, E., additional, Karp, S., additional, Kay, C., additional, Kellaway, J., additional, Khan, S., additional, Koh, D., additional, Light, T., additional, Limbu, P., additional, Lock, S., additional, Locke, I., additional, Loke, T., additional, Lowe, A., additional, Lucas, N., additional, Maheswaran, S., additional, Mallett, S., additional, Marwood, E., additional, McGowan, J., additional, Mckirdy, F., additional, Mills-Baldock, T., additional, Moon, T., additional, Morgan, V., additional, Morris, S., additional, Morton, A., additional, Nasseri, S., additional, Navani, N., additional, Nichols, P., additional, Norman, C., additional, Ntala, E., additional, Nunes, A., additional, Obichere, A., additional, O'Donohue, J., additional, Olaleye, I., additional, Oliver, A., additional, Onajobi, A., additional, O'Shaughnessy, T., additional, Padhani, A., additional, Pardoe, H., additional, Partridge, W., additional, Patel, U., additional, Perry, K., additional, Piga, W., additional, Prezzi, D., additional, Prior, K., additional, Punwani, S., additional, Pyers, J., additional, Rafiee, H., additional, Rahman, F., additional, Rajanpandian, I., additional, Ramesh, S., additional, Raouf, S., additional, Reczko, K., additional, Reinhardt, A., additional, Robinson, D., additional, Rockall, A., additional, Russell, P., additional, Sargus, K., additional, Scurr, E., additional, Shahabuddin, K., additional, Sharp, A., additional, Shepherd, B., additional, Shiu, K., additional, Sidhu, H., additional, Simcock, I., additional, Simeon, C., additional, Smith, A., additional, Smith, D., additional, Snell, D., additional, Spence, J., additional, Srirajaskanthan, R., additional, Stachini, V., additional, Stegner, S., additional, Stirling, J., additional, Strickland, N., additional, Tarver, K., additional, Teague, J., additional, Thaha, M., additional, Train, M., additional, Tulmuntaha, S., additional, Tunariu, N., additional, van Ree, K., additional, Verjee, A., additional, Wanstall, C., additional, Weir, S., additional, Wijeyekoon, S., additional, Wilson, J., additional, Wilson, S., additional, Win, T., additional, Woodrow, L., additional, and Yu, D., additional

Published
2020
Full Text
View/download PDF

12. Patient preferences for whole body MRI or conventional staging pathways in lung and colorectal cancer: a discrete choice experiment

Author

Miles, Anne, Taylor, S.A., Evans, R.E.C., Halligan, S., Beare, S., Bridgewater, J., Goh, V., Janes, S., Navani, N., Oliver, A., Morton, A., Rockall, A., Clarke, C.S., and Morris, S.

Subjects
psyc
Abstract

Objectives: To determine the importance placed by patients on attributes associated with whole body MRI (WB-MRI) and standard cancer staging pathways, and ascertain drivers of preference. \ud Methods: Patients recruited to two multi-centre diagnostic accuracy trials comparing WB-MRI with standard staging pathways in lung and colorectal cancer were invited to complete a discrete choice experiment (DCE), choosing between a series of alternate pathways in which 6 attributes (accuracy, time to diagnosis, scan duration, whole body enclosure, radiation exposure, total scan number) were varied systematically. Data were analysed using a conditional logit regression model and marginal rates of substitution computed. The relative importance of each attribute and probabilities of choosing WB-MRI based pathways were estimated.\ud Results: 138 patients (mean age 65, 61% male, lung n=72, colorectal n=66) participated (May 2015 to September 2016). Lung cancer patients valued, time to diagnosis most highly, followed by accuracy, radiation exposure, number of scans and time in the scanner. Colorectal cancer patients valued accuracy most highly, followed by time to diagnosis, radiation exposure and number of scans. Patients were willing wait 0.29 (lung), 0.45 (colorectal) weeks for a 1% increase in pathway accuracy. Patients preferred WB-MRI based pathways (probability 0.64 [lung], 0.66 [colorectal]) if they were equivalent in accuracy, total scan number, and time to diagnosis compared to a standard staging pathway. \ud Conclusions: Staging pathways based on first line WB-MRI are preferred by the majority of patients if they at least match standard pathways for diagnostic accuracy, time to diagnosis and total scan number.

Published
2019

13. Two Session Cognitive Bias Modification Training; Exercise Interpretation Bias

Author

Clarke, C.S., Mackintosh, B., and Cooper, N. R.

Subjects
BF
Abstract

Cognitive bias modification is the direct manipulation of a target bias by extensive exposure to task contingencies that encourage predetermined patterns of processing selectivity1,2. Forty-eight participants from a general population sample recruited for a two-part study investigating the effect of two sessions of exercise orientated Positive CBM-I Training, in comparison to a Neutral Pseudo Training condition. Baseline, post session one and post session two self-report measures of Anxiety, Depression and Stress were collected. Measures of interpretation bias were collected at baseline and post session two, both with and without cognitive load. Results suggest that for individuals undergoing two sessions of Positive CBM-I Training over a fortnight had significantly decreased Trait Anxiety scores, relative to the Pseudo Neutral Training condition. The findings hold promise for the Cognitive Bias Modification paradigm for decreasing symptoms of Anxiety.

Published
2018

16. Suicide and religiosity--Masaryk 's theory revisited.

Author

Clarke, C.S., Bannon, F.J., and Denihan, A.

Subjects
*SUICIDE, *SOCIAL change, *SECULARISM, *CULTURE
Abstract

Reports on a study which shows evidence of an inverse relationship between religiosity and suicide when age and gender are considered. Comparison of the national suicide rates with the results of a survey on religious belief and practice conducted during the same year.

Published
2003
Full Text
View/download PDF

18. A0534 - Comparison of biparametric and multiparametric magnetic resonance imaging for prostate cancer detection: an 8-month update on the PRIME Study (NCT04571840).

Author

Ng, A., Asif, A., Nathan, A., Khetrapal, P., Chan, V.W.S., Rossiter, M., Punwani, S., Clarke, C.S., Brew-Graves, C., Emberton, M., Agarwal, R., Takwoingi, Y., Deeks, J., Giganti, F., Allen, C., Moore, C.M., Kasivisvanathan, V., and Prime, S.

Subjects
*MAGNETIC resonance imaging, *EARLY detection of cancer, *PROSTATE cancer
Published
2023
Full Text
View/download PDF

19. What experts think about prostate cancer management during the COVID-19 pandemic: report from The Advanced Prostate Cancer Consensus Conference 2021

Author

Fabio Turco, Andrew Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, Orazio Caffo, Kim N. Chi, Caroline Clarke, Noel Clarke, Ian D. Davis, Johann de Bono, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Jason Efstathiou, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Karim Fizazi, Mark Frydenberg, Dan George, Martin Gleave, Susan Halabi, Daniel Heinrich, Celestia Higano, Michael S. Hofman, Maha Hussain, Nicholas James, Rob Jones, Ravindran Kanesvaran, Raja B. Khauli, Laurence Klotz, Raya Leibowitz, Christopher Logothetis, Fernando Maluf, Robin Millman, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Hind Mrabti, Declan G. Murphy, Vedang Murthy, William K. Oh, Ngozi Ekeke Onyeanunam, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Christopher Parker, Darren M.C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Mark Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Neal Shore, Iwona Skoneczna, Eric Small, Matthew Smith, Howard Soule, Daniel Spratt, Cora N. Sternberg, Hiroyoshi Suzuki, Christopher Sweeney, Matthew Sydes, Mary-Ellen Taplin, Derya Tilki, Bertrand Tombal, Levent Türkeri, Hiroji Uemura, Hirotsugu Uemura, Inge van Oort, Kosj Yamoah, Dingwei Ye, Almudena Zapatero, Silke Gillessen, Aurelius Omlin, Tilki, Derya, Turco, F., Armstrong, A., Attard, G., Beer, T.M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R.G., Bulbul, M., Caffo, O., Chi, K.N., Clarke, C.S., Clarke, N., Davis, I.D., de Bono, J., Duran, I., Eeles, R., Efstathiou, E., Efstathiou, J., Evans, C.P., Fanti, S., Feng, F.Y., Fizazi, K., Frydenberg, M., George, D., Gleave, M., Halabi, S., Heinrich, D., Higano, C., Hofman, M.S., Hussain, M., James, N., Jones, R., Kanesvaran, R., Khauli, R.B., Klotz, L., Leibowitz, R., Logothetis, C., Maluf, F., Millman, R., Morgans, A.K., Morris, M.J., Mottet, N., Mrabti, H., Murphy, D.G., Murthy, V., Oh, W.K., Ekeke, O.N., Ost, P., O'Sullivan, J.M., Padhani, A.R., Parker, C., Poon, D.M.C., Pritchard, C.C., Rabah, D.M., Rathkopf, D., Reiter, R.E., Rubin, M., Ryan, C.J., Saad, F., Sade, J.P., Sartor, O., Scher, H.I., Shore, N., Skoneczna, I., Small, E., Smith, M., Soule, H., Spratt, D.E., Sternberg, C.N., Suzuki, H., Sweeney, C., Sydes, M.R., Taplin, M.-E., Tombal, B., Türkeri, L., Uemura, H., van Oort, I., Yamoah, K., Ye, D., Zapatero, A., Gillessen, S., Omlin, A., Koç University Hospital, School of Medicine, Acibadem University Dspace, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, and UCL - (SLuc) Service d'urologie

Subjects
Male, COVID-19 Vaccines, Prostate cancer, Urology, COVID-19 boost injection, COVID-19 pandemic, COVID-19 vaccine, Prostate cancer management, Telemedicine, COVID-19, Prostatic Neoplasms, Androgen Antagonists, 610 Medicine & health, Urology and nephrology, SDG 3 - Good Health and Well-being, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Humans, Pandemics
Abstract

Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert's treatment recommendations are influenced by the vaccination status: the COVID-19 pandemic altered management of APC patients for 70% of the panellists before the vaccination was available but only for 25% of panellists for fully vaccinated patients. Most experts (71%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients. Patient summary: In the Advanced Prostate Cancer Consensus Conference 2021, the panellists reached a consensus regarding the recommendation of the COVID-19 vaccine in prostate cancer patients and use of telemedicine for monitoring these patients., NA

Published
2022
Full Text
View/download PDF

20. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021

Author

Silke Gillessen, Andrew Armstrong, Gert Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Robert G. Bristow, Muhammad Bulbul, Orazio Caffo, Kim N. Chi, Caroline S. Clarke, Noel Clarke, Ian D. Davis, Johann S. de Bono, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Jason Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Karim Fizazi, Mark Frydenberg, Dan George, Martin Gleave, Susan Halabi, Daniel Heinrich, Celesta Higano, Michael S. Hofman, Maha Hussain, Nick James, Robert Jones, Ravindran Kanesvaran, Raja B. Khauli, Laurence Klotz, Raya Leibowitz, Chris Logothetis, Fernando Maluf, Robin Millman, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Hind Mrabti, Declan G. Murphy, Vedang Murthy, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Chris Parker, Darren M.C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Rob E. Reiter, Mark Rubin, Charles J. Ryan, Fred Saad, Juan P. Sade, Oliver Sartor, Howard I. Scher, Neal Shore, Iwona Skoneczna, Eric Small, Matthew Smith, Howard Soule, Daniel E. Spratt, Cora N. Sternberg, Hiroyoshi Suzuki, Christopher Sweeney, Matthew R. Sydes, Mary-Ellen Taplin, Derya Tilki, Bertrand Tombal, Levent Türkeri, Hiroji Uemura, Hirotsugu Uemura, Inge van Oort, Kosj Yamoah, Dingwei Ye, Almudena Zapatero, Aurelius Omlin, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, Acibadem University Dspace, Gillessen, Silke, Armstrong, Andrew, Attard, Gert, Beer, Tomasz M, Beltran, Himisha, Bjartell, Ander, Bossi, Alberto, Briganti, Alberto, Bristow, Robert G, Bulbul, Muhammad, Caffo, Orazio, Chi, Kim N, Clarke, Caroline S, Clarke, Noel, Davis, Ian D, de Bono, Johann S, Duran, Ignacio, Eeles, Ro, Efstathiou, Eleni, Efstathiou, Jason, Ekeke, Onyeanunam Ngozi, Evans, Christopher P, Fanti, Stefano, Feng, Felix Y, Fizazi, Karim, Frydenberg, Mark, George, Dan, Gleave, Martin, Halabi, Susan, Heinrich, Daniel, Higano, Celesta, Hofman, Michael S, Hussain, Maha, James, Nick, Jones, Robert, Kanesvaran, Ravindran, Khauli, Raja B, Klotz, Laurence, Leibowitz, Raya, Logothetis, Chri, Maluf, Fernando, Millman, Robin, Morgans, Alicia K, Morris, Michael J, Mottet, Nicola, Mrabti, Hind, Murphy, Declan G, Murthy, Vedang, Oh, William K, Ost, Piet, O'Sullivan, Joe M, Padhani, Anwar R, Parker, Chri, Poon, Darren M C, Pritchard, Colin C, Rabah, Danny M, Rathkopf, Dana, Reiter, Rob E, Rubin, Mark, Ryan, Charles J, Saad, Fred, Sade, Juan P, Sartor, Oliver, Scher, Howard I, Shore, Neal, Skoneczna, Iwona, Small, Eric, Smith, Matthew, Soule, Howard, Spratt, Daniel E, Sternberg, Cora N, Suzuki, Hiroyoshi, Sweeney, Christopher, Sydes, Matthew R, Taplin, Mary-Ellen, Tilki, Derya, Tombal, Bertrand, Türkeri, Levent, Uemura, Hiroji, Uemura, Hirotsugu, van Oort, Inge, Yamoah, Kosj, Ye, Dingwei, Zapatero, Almudena, Omlin, Aurelius, Gillessen, S., Armstron, A., Attard, G., Beer, T.M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R.G., Bulbul, M., Caffo, O., Chi, K.N., Clarke, C.S., Clarke, N., Davis, I.D., de Bono, J.S., Duran, I., Eeles, R., Efstathiou, E., Efstathiou, J., Ekeke, O.N., Evans, C.P., Fanti, S., Feng, F.Y., Fizazi, K., Frydenberg, M., George, D., Gleave, M., Halabi, S., Heinrich, D., Higano, C., Hofman, M.S., Hussain, M., James, N., Jones, R., Kanesvaran, R., Khauli, R.B., Klotz, L., Leibowitz, R., Logothetis, C., Maluf, F., Millman, R., Morgans, A.K., Morris, M.J., Mottet, N., Mrabti, H., Murphy, D.G., Murthy, V., Oh, W.K., Ost, P., O'Sullivan, J.M., Padhani, A.R., Parker, C., Poon, D.M.C., Pritchard, C.C., Rabah, D.M., Rathkopf, D., Reiter, R.E., Rubin, M., Ryan, C.J., Saad, F., Sade, J.P., Sartor, O., Scher, H.I., Shore, N., Skoneczna, I., Small, E., Smith, M., Soule, H., Spratt, D.E., Sternberg, C.N., Suzuki, H., Sweeney, C., Sydes, M.R., Taplin, M.E., Tombal, B., Türkeri, L., Uemura, H., van Oort, I., Yamoah, K., Ye, D., Zapatero, A., Omlin, A., Koç University Hospital, and School of Medicine

Subjects
Male, Consensus, Urology, education, Lu-177-PSMA therapy, Consensu, Hormone-sensitive prostate cancer, Imaging, SDG 3 - Good Health and Well-being, Genetic, Lu-PSMA therapy, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Genetics, Humans, Castration-resistant prostate cancer, Tumour genomic profiling, Manchester Cancer Research Centre, Advanced prostate cancer, ResearchInstitutes_Networks_Beacons/mcrc, PARP inhibition, 177Lu-PSMA therapy, Next-generation sequencing, Prostate cancer treatment, Prostatic Neoplasms, Urology and nephrology, (177)Lu-PSMA therapy, Human
Abstract

Background: innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. The 2021 Advanced Prostate Cancer Consensus Conference (APCCC) addressed some of these questions to supplement guidelines that are based on level 1 evidence. Objective: to present the voting results from APCCC 2021. Design, setting, and participants: the experts identified three major areas of controversy related to management of advanced prostate cancer: newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), the use of prostate-specific membrane antigen ligands in diagnostics and therapy, and molecular characterisation of tissue and blood. A panel of 86 international prostate cancer experts developed the programme and the consensus questions. Outcome measurements and statistical analysis: The panel voted publicly but anonymously on 107 pre-defined questions, which were developed by both voting and non-voting panel members prior to the conference following a modified Delphi process. Results and limitations: the voting reflected the opinions of panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results reported in the Supplementary material. Conclusions: these voting results from a panel of experts in advanced prostate cancer can help clinicians and patients to navigate controversial areas of management for which high-level evidence is scant. However, diagnostic and treatment decisions should always be individualised according to patient characteristics, such as the extent and location of disease, prior treatment(s), comorbidities, patient preferences, and treatment recommendations, and should also incorporate current and emerging clinical evidence and logistic and economic constraints. Enrolment in clinical trials should be strongly encouraged. Importantly, APCCC 2021 once again identified salient questions that merit evaluation in specifically designed trials. Patient summary: the Advanced Prostate Cancer Consensus Conference is a forum for discussing current diagnosis and treatment options for patients with advanced prostate cancer. An expert panel votes on predefined questions focused on the most clinically relevant areas for treatment of advanced prostate cancer for which there are gaps in knowledge. The voting results provide a practical guide to help clinicians in discussing treatment options with patients as part of shared decision-making., National Health and Medical Research Council (NHMRC) Practitioner Fellowship; Prostate Cancer Foundation; Peter MacCallum Foundation; NHMRC Investigator Grant

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results